Schilke Tobin

Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) · Chief Financial Officer

Schilke Tobin is listed in public filings as officer: Chief Financial Officer. This Schilke Tobin insider trading page organizes Form 4 disclosures, reported purchases and sales, transaction dates, share amounts, related issuers, and historical insider activity so readers can review the person's public trading record in one place. Companies and tickers connected to this insider trading profile include Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) (CRNX), and Revance Therapeutics, Inc. - Common Stock (RVNC). Investors use Schilke Tobin's insider trading disclosures to study buying and selling patterns, position changes, company-specific activity, and the source evidence behind each reported transaction.

Latest Actions

CompanyHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)CRNX$3.1M78.1k sharesSellMar 3, 2026$266.3K6.7k shares$39.67--

Insider Trades History

CompanyHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)CRNX$2.2M50k sharesGrant / ExerciseFeb 23, 2026$2.2M50k shares$43.79--
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)CRNX--84.8k sharesGrant / ExerciseFeb 23, 2026Disclosure amount unavailable32k shares----
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)CRNX$2.7M80k sharesGrant / ExerciseMar 10, 2025$2.7M80k shares$33.75--
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)CRNX--52k sharesGrant / ExerciseMar 10, 2025Disclosure amount unavailable52k shares----
Revance Therapeutics, Inc. - Common StockRVNC--20.9k sharesOtherFeb 6, 2025Disclosure amount unavailable20.9k shares----
Revance Therapeutics, Inc. - Common StockRVNC--20.9k sharesGrant / ExerciseFeb 6, 2025Disclosure amount unavailable20.9k shares----
Revance Therapeutics, Inc. - Common StockRVNC$378k103.6k sharesOtherFeb 4, 2025$357.7K98k shares$3.65--
Revance Therapeutics, Inc. - Common StockRVNC--201.6k sharesGrant / ExerciseFeb 3, 2025Disclosure amount unavailable6.9k shares----
Revance Therapeutics, Inc. - Common StockRVNC$425k194.7k sharesGrant / ExerciseDec 31, 2024$2.2K1k shares$2.18--
Revance Therapeutics, Inc. - Common StockRVNC$423k193.7k sharesGrant / ExerciseJun 30, 2024$2.2K1k shares$2.18--